- Biopharma dealmaking in 2026: The recovery gathers speed in Q2It’s always darkest before the biotech dawn, and at no time was that more true than last summer, as biotech was experiencing a crisis of confidence. We tracked an industry-wide downturn in expect…Endpoints · 2d ago↗ source
- Vertex was only bidder for Crinetics in year's second-highest M&A premiumTo gain control of Crinetics Pharmaceuticals, Vertex Pharmaceuticals was willing to pay the second-highest premium so far in biopharma's banner year for M&A. And the Boston drugmaker was biddin…Endpoints · 2d ago↗ source
- Trump pledges new tariffs on generic drugs not made in the USPresident Donald Trump on Tuesday evening said he will impose up to 200% tariffs on generic drugs sold in the US, if companies do not manufacture those medicines in America. Trump said that for t…